Additional Cariprazine Trial Could Put Forest In A Better Competitive Position
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA “complete response” letter seeks another trial to better define the most tolerable dose, which could get the atypical antipsychotic to market in a better position than the original dataset.